Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
The Prevalence and Prognostic Value of Neuroimaging Abnormalities in the Acut...CrimsonPublishersTNN
The Prevalence and Prognostic Value of Neuroimaging Abnormalities in the Acute Phase of Sepsis-Associated Encephalopathy by Keenan A Walker in Techniques in Neurosurgery & Neurology
Neurological Pupil Index as an Indicator of Irreversible Cerebral Edema: A Ca...NeurOptics, Inc.
Assessing the pupillary light reflex (PLR) is acore component of neurological assessments. Changes in pupil size and reactivity can provide early recognition of neurological decline and facilitate lifesaving interventions.
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
This randomized controlled trial evaluated whether pre-hospital administration of hypertonic saline or hypertonic saline plus dextran improved 6-month neurological outcomes in patients with severe traumatic brain injury without hypovolaemic shock compared to normal saline. Over 1300 patients were randomized to receive one of the three study fluids. The primary outcome of an extended Glasgow Outcome Scale score of ≤4 at 6 months was not significantly different between groups. Secondary outcomes including 28-day survival were also not significantly different between groups. The study was terminated early due to futility in showing benefit of the hypertonic fluids over normal saline.
Neurocysticercosis the notorious vanishing ring enhancing lesion ijar feb 2015Sachin Adukia
This document summarizes a study of 25 patients presenting with ring enhancing lesions (RELs) on MRI brain scans. The study aimed to evaluate clinical features and diagnoses of RELs and treatment outcomes. Of the 25 patients, 8 (32%) were diagnosed with neurocysticercosis based on clinical features, investigations and MRI findings. All 8 neurocysticercosis patients presented with seizures and most with headache. Lesions were typically solitary and less than 10mm. Treatment with albendazole, anti-convulsants and steroids resulted in complete resolution in 6 patients (75%) and regression/calcification in the remaining 2, demonstrating neurocysticercosis has an excellent prognosis with appropriate treatment.
The document discusses home care for patients with neuromuscular diseases, specifically focusing on whether general practitioners or specialized teams are better suited to provide care. It notes the benefits of both approaches but emphasizes the importance of support networks and multidisciplinary teams to ensure accessible, high quality, and personalized care for patients.
This study compared intravenous levetiracetam (LEV) to intravenous phenytoin (PHT) for seizure prophylaxis in patients with severe traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) admitted to the neuroscience intensive care unit (NSICU). Fifty-two patients were randomized to receive either LEV (n=34) or PHT (n=18). Continuous EEG monitoring was performed for 72 hours. Long-term outcomes including Disability Rating Scale scores and Glasgow Outcome Scale scores were better in the LEV group compared to the PHT group at 3 and 6 months, respectively, after controlling for baseline severity. There were no significant differences in seizure rates
Bach Pharma Inc. is developing GVT, a potential solution of neurodegenerative diseases for U.S. distribution. Find out about GVT and our current fundraising goals.
Statistical, Energy Values And Peak Analysis (SEP) Approach For Detection of ...IJMERJOURNAL
ABSTRACT: In this paper, a technique of statistical, Energy values and peak analysis (SEP) approach is used for detection of neurodegenerative diseases from the signal of force sensitive resistors. In this work within the time series Left Stride Interval, Right Stride Interval, Left Swing Interval, Right Swing Interval, Left Stance Interval, Right Stance Interval and Double support interval are obtained and apply the SEP method. In statistical analysis, energy, standard deviation, mean, variance, co-variance are calculated. Two approximations and two details of energy values are extracted from wavelet decomposition. Average peak interval and peak histogram are calculated using peak analysis. Support Vector Machine (SVM) and Random Forest are used as a classifier. Data sets which include a healthy control (HC), various types of Neuro degenerative Diseases: Parkinson’s Disease (PD), Huntington Disease (HD), Amyotrophic Lateral Sclerosis. For disease diagnostic Force Sensitive resistor signals are used for evaluation. The results show that the proposed technique can successfully detect the NDD pathologies. For NDD detection, the accuracy, the Sensitivity, the Specificity values are 97%, 97% and 97% using Random forest Classifier.
Hypothermia for Neonatal Hypoxic Ischemic EncephalopathyMaged Zakaria
This review article summarizes the current evidence on therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy (HIE) from randomized controlled trials. The review identified 7 trials including 1214 newborns that compared therapeutic hypothermia to normothermia. The results showed that therapeutic hypothermia reduced the risk of death or major neurodevelopmental disability at 18 months and increased the rate of survival with normal neurological function. Both total body cooling and selective head cooling were effective in reducing these risks. The review concludes that hypothermia improves outcomes for newborns with moderate to severe HIE and should be considered as part of routine clinical care for these newborns.
Si nous portions un nouveau regard sur le syndrome d'encéphalite aiguë chez le sujet jeune ? Il faut penser aujourd'hui à évoquer l'Encéphalite Auto-Immune à Anticorps Anti-Récepteurs NMDA ! Vous sauverez des vies à l'évoquer devant toute épilepsie atypique et/ou psychose inaugurale associée à un signe discordant.
This document lists publications by Kari J. Reinikainen including original papers, reviews, and pharmaceutical experience. It provides a list of 48 publications from 1978-1991 related to neurology, neurotransmitters, Alzheimer's disease, and other topics. Reinikainen's publications examined changes in neurotransmitters and receptors in Alzheimer's disease and other conditions. Many publications involved analysis of cerebrospinal fluid markers and post-mortem brain tissue. Reinikainen's work contributed to understanding of neurochemical changes in neurological and psychiatric conditions.
This document discusses what brain health is in the context of multiple sclerosis (MS). It provides an overview of factors related to brain health for people with MS, including risks, symptoms, diagnostic criteria, treatments, management strategies, and lifestyle factors. The document emphasizes that early intervention and treatment is important for brain health in MS, as time matters, and delayed treatment can lead to worse long-term outcomes and prognosis. It presents evidence that earlier treatment may provide benefits in reducing relapses and disability progression.
Neurocritical Care Triad - Focused Neurological Examination, Brain Multimodal...Apollo Hospitals
Intensive care is rightly described as “an art of managing intense intricacy” and this situation is further complicated in the care of patients with critical neurological illness. Brain
damage directly related to an insult is primary brain injury (PBI). The cascade of pathobiological events following PBI is known as secondary brain injury (SBI). PBI is most often
irreversible so, the focus of neurocritical care is to prevent, detect and manage SBI.
Medicines For Respiratory Diseases
Apneas: Types, Their Measurement, Epidemiology, and Economics
Dronabinol: Breakthrough Treatment for Obstructive Sleep
Apnea
"Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit, the same word means both breath and life."
Abbot George Burke
This study examines changes in dendritic branching and spines in the frontal, temporal, and parietal cortex from individuals diagnosed as non-cognitively impaired (NCI), with mild cognitive impairment (MCI), or with Alzheimer's disease (AD). Brain tissue was analyzed using the Golgi impregnation method to quantify dendritic branching and spines. Results showed each cortical region had distinct patterns of dendritic changes from NCI to MCI to AD. The temporal cortex saw a 20% loss of branching in MCI and a further 5% loss in AD. The parietal cortex had a mild 4% loss in MCI and a 10% loss in AD. In contrast, the frontal cortex showed a
Is It Important to Determine Who Will Develop Alzheimer’s?Ross Finesmith
This document discusses whether it is important to determine who will develop Alzheimer's disease. While past studies tried to predict who would develop Alzheimer's, the information had little clinical benefit when there were no effective treatments. New research using blood biomarkers has shown promise in identifying over 90% of cognitively normal individuals who will develop mild cognitive impairment or Alzheimer's within a few years. If pre-clinical individuals can be identified, disease-modifying treatments targeted to prevent irreversible pathological changes may prove useful by preventing manifestation of the disease.
Alzheimer's Disease and Other Dementias by ARLYN M. VALENCIA , M.D.. Neurolog...Arlyn Valencia, M.D.
This document discusses Alzheimer's disease and other dementias. It defines Alzheimer's disease as a neurodegenerative disease caused by amyloid plaques and tau tangles in the brain. It differentiates Alzheimer's from other dementias such as frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, and normal pressure hydrocephalus. The document discusses risk factors, symptoms, diagnostic tools, treatments, and future targets for therapies for Alzheimer's and other dementias.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
The Prevalence and Prognostic Value of Neuroimaging Abnormalities in the Acut...CrimsonPublishersTNN
The Prevalence and Prognostic Value of Neuroimaging Abnormalities in the Acute Phase of Sepsis-Associated Encephalopathy by Keenan A Walker in Techniques in Neurosurgery & Neurology
Neurological Pupil Index as an Indicator of Irreversible Cerebral Edema: A Ca...NeurOptics, Inc.
Assessing the pupillary light reflex (PLR) is acore component of neurological assessments. Changes in pupil size and reactivity can provide early recognition of neurological decline and facilitate lifesaving interventions.
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
This randomized controlled trial evaluated whether pre-hospital administration of hypertonic saline or hypertonic saline plus dextran improved 6-month neurological outcomes in patients with severe traumatic brain injury without hypovolaemic shock compared to normal saline. Over 1300 patients were randomized to receive one of the three study fluids. The primary outcome of an extended Glasgow Outcome Scale score of ≤4 at 6 months was not significantly different between groups. Secondary outcomes including 28-day survival were also not significantly different between groups. The study was terminated early due to futility in showing benefit of the hypertonic fluids over normal saline.
Neurocysticercosis the notorious vanishing ring enhancing lesion ijar feb 2015Sachin Adukia
This document summarizes a study of 25 patients presenting with ring enhancing lesions (RELs) on MRI brain scans. The study aimed to evaluate clinical features and diagnoses of RELs and treatment outcomes. Of the 25 patients, 8 (32%) were diagnosed with neurocysticercosis based on clinical features, investigations and MRI findings. All 8 neurocysticercosis patients presented with seizures and most with headache. Lesions were typically solitary and less than 10mm. Treatment with albendazole, anti-convulsants and steroids resulted in complete resolution in 6 patients (75%) and regression/calcification in the remaining 2, demonstrating neurocysticercosis has an excellent prognosis with appropriate treatment.
The document discusses home care for patients with neuromuscular diseases, specifically focusing on whether general practitioners or specialized teams are better suited to provide care. It notes the benefits of both approaches but emphasizes the importance of support networks and multidisciplinary teams to ensure accessible, high quality, and personalized care for patients.
This study compared intravenous levetiracetam (LEV) to intravenous phenytoin (PHT) for seizure prophylaxis in patients with severe traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) admitted to the neuroscience intensive care unit (NSICU). Fifty-two patients were randomized to receive either LEV (n=34) or PHT (n=18). Continuous EEG monitoring was performed for 72 hours. Long-term outcomes including Disability Rating Scale scores and Glasgow Outcome Scale scores were better in the LEV group compared to the PHT group at 3 and 6 months, respectively, after controlling for baseline severity. There were no significant differences in seizure rates
Bach Pharma Inc. is developing GVT, a potential solution of neurodegenerative diseases for U.S. distribution. Find out about GVT and our current fundraising goals.
Statistical, Energy Values And Peak Analysis (SEP) Approach For Detection of ...IJMERJOURNAL
ABSTRACT: In this paper, a technique of statistical, Energy values and peak analysis (SEP) approach is used for detection of neurodegenerative diseases from the signal of force sensitive resistors. In this work within the time series Left Stride Interval, Right Stride Interval, Left Swing Interval, Right Swing Interval, Left Stance Interval, Right Stance Interval and Double support interval are obtained and apply the SEP method. In statistical analysis, energy, standard deviation, mean, variance, co-variance are calculated. Two approximations and two details of energy values are extracted from wavelet decomposition. Average peak interval and peak histogram are calculated using peak analysis. Support Vector Machine (SVM) and Random Forest are used as a classifier. Data sets which include a healthy control (HC), various types of Neuro degenerative Diseases: Parkinson’s Disease (PD), Huntington Disease (HD), Amyotrophic Lateral Sclerosis. For disease diagnostic Force Sensitive resistor signals are used for evaluation. The results show that the proposed technique can successfully detect the NDD pathologies. For NDD detection, the accuracy, the Sensitivity, the Specificity values are 97%, 97% and 97% using Random forest Classifier.
Hypothermia for Neonatal Hypoxic Ischemic EncephalopathyMaged Zakaria
This review article summarizes the current evidence on therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy (HIE) from randomized controlled trials. The review identified 7 trials including 1214 newborns that compared therapeutic hypothermia to normothermia. The results showed that therapeutic hypothermia reduced the risk of death or major neurodevelopmental disability at 18 months and increased the rate of survival with normal neurological function. Both total body cooling and selective head cooling were effective in reducing these risks. The review concludes that hypothermia improves outcomes for newborns with moderate to severe HIE and should be considered as part of routine clinical care for these newborns.
Si nous portions un nouveau regard sur le syndrome d'encéphalite aiguë chez le sujet jeune ? Il faut penser aujourd'hui à évoquer l'Encéphalite Auto-Immune à Anticorps Anti-Récepteurs NMDA ! Vous sauverez des vies à l'évoquer devant toute épilepsie atypique et/ou psychose inaugurale associée à un signe discordant.
This document lists publications by Kari J. Reinikainen including original papers, reviews, and pharmaceutical experience. It provides a list of 48 publications from 1978-1991 related to neurology, neurotransmitters, Alzheimer's disease, and other topics. Reinikainen's publications examined changes in neurotransmitters and receptors in Alzheimer's disease and other conditions. Many publications involved analysis of cerebrospinal fluid markers and post-mortem brain tissue. Reinikainen's work contributed to understanding of neurochemical changes in neurological and psychiatric conditions.
This document discusses what brain health is in the context of multiple sclerosis (MS). It provides an overview of factors related to brain health for people with MS, including risks, symptoms, diagnostic criteria, treatments, management strategies, and lifestyle factors. The document emphasizes that early intervention and treatment is important for brain health in MS, as time matters, and delayed treatment can lead to worse long-term outcomes and prognosis. It presents evidence that earlier treatment may provide benefits in reducing relapses and disability progression.
Neurocritical Care Triad - Focused Neurological Examination, Brain Multimodal...Apollo Hospitals
Intensive care is rightly described as “an art of managing intense intricacy” and this situation is further complicated in the care of patients with critical neurological illness. Brain
damage directly related to an insult is primary brain injury (PBI). The cascade of pathobiological events following PBI is known as secondary brain injury (SBI). PBI is most often
irreversible so, the focus of neurocritical care is to prevent, detect and manage SBI.
Medicines For Respiratory Diseases
Apneas: Types, Their Measurement, Epidemiology, and Economics
Dronabinol: Breakthrough Treatment for Obstructive Sleep
Apnea
"Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit, the same word means both breath and life."
Abbot George Burke
This study examines changes in dendritic branching and spines in the frontal, temporal, and parietal cortex from individuals diagnosed as non-cognitively impaired (NCI), with mild cognitive impairment (MCI), or with Alzheimer's disease (AD). Brain tissue was analyzed using the Golgi impregnation method to quantify dendritic branching and spines. Results showed each cortical region had distinct patterns of dendritic changes from NCI to MCI to AD. The temporal cortex saw a 20% loss of branching in MCI and a further 5% loss in AD. The parietal cortex had a mild 4% loss in MCI and a 10% loss in AD. In contrast, the frontal cortex showed a
Is It Important to Determine Who Will Develop Alzheimer’s?Ross Finesmith
This document discusses whether it is important to determine who will develop Alzheimer's disease. While past studies tried to predict who would develop Alzheimer's, the information had little clinical benefit when there were no effective treatments. New research using blood biomarkers has shown promise in identifying over 90% of cognitively normal individuals who will develop mild cognitive impairment or Alzheimer's within a few years. If pre-clinical individuals can be identified, disease-modifying treatments targeted to prevent irreversible pathological changes may prove useful by preventing manifestation of the disease.
Alzheimer's Disease and Other Dementias by ARLYN M. VALENCIA , M.D.. Neurolog...Arlyn Valencia, M.D.
This document discusses Alzheimer's disease and other dementias. It defines Alzheimer's disease as a neurodegenerative disease caused by amyloid plaques and tau tangles in the brain. It differentiates Alzheimer's from other dementias such as frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, and normal pressure hydrocephalus. The document discusses risk factors, symptoms, diagnostic tools, treatments, and future targets for therapies for Alzheimer's and other dementias.
The document provides an introduction to the Buck Institute's Alzheimer's/Mild Cognitive Impairment Program. It summarizes that the program aims to develop novel therapeutic candidates for Alzheimer's disease by identifying compounds that interact with the amyloid precursor protein (APP) or other members of the underlying biological network. Three classes of drug candidates are being researched: 1) the endogenous protein netrin-1, 2) several small molecule compounds identified in screens, including a lead candidate called F03, and 3) analogs of F03 and other hits with improved properties. The Buck Institute is pursuing clinical development of F03 and seeking partners to collaborate on additional candidate drugs.
Parkinson’s disease detection system using Support vector machineIRJET Journal
This document summarizes a research paper on developing a Parkinson's disease detection system using support vector machines (SVM). The researchers collected vocal data from patients and trained an SVM model to classify Parkinson's disease based on vocal features. They preprocessed the data, split it into training and test sets, and trained the SVM model. The model achieved accurate detection of Parkinson's disease on both the training and test sets. In the future, the researchers aim to improve the system by connecting it to microphones to allow direct user input and linking users to doctors. The system is intended to help detect Parkinson's disease earlier.
A SURVEY ON PARKINSON’S DISEASE DETECTION TECHNIQUESIRJET Journal
This document discusses techniques for detecting Parkinson's disease through analysis of voice recordings. It provides an overview of several machine learning and deep learning algorithms that have been applied to classify Parkinson's disease based on voice data, including artificial neural networks, random forest classifiers, convolutional neural networks and adaptive backpropagation neural networks. Accuracy rates between 85-88% were reported. The document also discusses the use of techniques like fuzzy C-means clustering and efficient randomized feature selection algorithms to improve Parkinson's disease detection from voice recordings.
Parkinson s disease gene therapy success by design meets failure by efficacy ...Elsa von Licy
The document discusses 9 gene therapy clinical trials conducted over the past decade to treat Parkinson's disease. None of the trials have produced sufficiently robust clinical efficacy to enable approval, despite demonstrating safety. The trials collectively show gene therapy can safely generate biologically active proteins in the brain without risk or harm. However, improved clinical trial design, patient selection, outcome measures, and animal models are still needed to advance efficacy. The trials represent progress for the gene therapy field, but a renewed focus on efficacy is required to move programs forward.
2015 Suarez-Gonzalez et al PCA Psychiatr Clin North AmDr Susie Henley
This document summarizes research on neuropsychiatric manifestations (NPM) in posterior cortical atrophy (PCA), an atypical form of Alzheimer's disease. It finds that apathy, anxiety, depression and irritability are the most common NPM in PCA. While NPM rates are high in PCA as in other dementias, the profile may differ in that anxiety is particularly prevalent compared to typical Alzheimer's. Younger age of onset in PCA could also influence NPM patterns compared to late-onset Alzheimer's. The neuropsychiatric examination is important for diagnosis and treatment of NPM in PCA.
This document discusses biomarkers for epileptogenesis and the challenges in developing clinically useful biomarkers to predict epilepsy risk, progression, and treatment response. It notes that while many potential biomarkers have been identified in preclinical studies, none have translated to clinical use. Some key challenges include the long timescales between injury and seizures, heterogeneity of epilepsy types and patients, and a focus on retrospective studies in refractory epilepsy patients rather than prospective validation. The document argues that combinatorial biomarkers analyzing multiple mechanisms may be more promising than single biomarkers, and that biomarkers should be validated as direct measures of patient outcomes rather than relying solely on seizure occurrence.
This document describes a proof of concept for using big data analytics of electronic health records to assess treatment efficacy for retinal conditions. It analyzes data from two retinal specialists on treatments for central retinal vein occlusion and branch retinal vein occlusion. The analysis found that dexamethasone and bevacizumab seemed to produce larger increases in visual acuity over 12 months compared to other treatments, but that sample sizes were limited. For CRVO, ranibizumab produced a modestly lower decrease in intraocular pressure than dexamethasone, while both reduced foveal thickness similarly. The software allows physicians to generate individual and aggregate plots of patient outcomes over time to help guide more personalized and effective treatment decisions.
The document summarizes 10 healthcare innovation projects presented at the DayOne Conference. The projects cover a range of areas including biomarkers and disease monitoring, digital health platforms to improve communication between patients and doctors, technologies for more precise diagnosis and treatment, and systems to empower patients and improve healthcare delivery. Many of the projects utilize new technologies like artificial intelligence, mobile apps, and sensors to work towards more preventative, personalized, and cost-effective healthcare.
Heart Failure Prediction using Different Machine Learning TechniquesIRJET Journal
The document compares the effectiveness of four machine learning methods - Random Forest, K-nearest neighbors, Naive Bayes, and Logistic Regression - for predicting heart failure using a publicly available dataset. It finds that Random Forest delivers the highest performance score of 90.16% accuracy, outperforming the other methods. The document outlines the methodology used, including a description of the dataset and features, and provides details on each of the four machine learning techniques evaluated for the heart failure prediction task.
This document summarizes nuclear medicine imaging techniques for diagnosing dementia. It discusses how [18F]FDG PET has been used to detect changes in brain glucose metabolism associated with Alzheimer's disease (AD), often years before symptoms appear. More recently, PET imaging of amyloid-β plaques has provided a way to detect a key pathological feature of AD in living patients. The document reviews these nuclear medicine approaches and their potential to improve early detection and differential diagnosis of dementia.
This document discusses a student research project aimed at developing new drug leads for Alzheimer's disease by targeting beta-secretase, an enzyme involved in the production of amyloid beta peptides. It provides background on Alzheimer's disease mechanisms and treatments. The project will use rational drug design methods to develop small molecule beta-secretase inhibitors, which will then be patented and licensed to a company for further development as a potential pharmaceutical.
Diabetic retinopathy management an advanced approach gonzalezDiopsys, Inc.
Electroretinography (ERG) provides objective information about retinal function that can help doctors better manage diabetic retinopathy. Specifically, flicker ERG testing measures cone cell response and can identify early retinal changes, stage disease severity, and evaluate treatment effectiveness. By detecting functional changes not seen with visual acuity tests alone, ERG allows for improved decision-making regarding treatment options and goals of care for the millions of Americans with diabetic retinopathy.
UCSF08 - EPGP_Pharmacogenomics_Award_2008_SubmissionMichael Williams
The document describes a pharmacogenomics research informatics project at the University of California, San Francisco called the Epilepsy Phenome Genome Project (EPGP). The EPGP received $15 million to study the genetic factors underlying common forms of epilepsy. It involves collecting detailed phenotypic data on epilepsy patients and controls to identify genetic contributions to epilepsy, brain development anomalies, and responses to antiepileptic drug (AED) treatments. The project developed a web-based tool to efficiently capture pharmacogenomics data across 15 EPGP clinical sites. This tool collects detailed AED drug histories and will provide an immense source of new knowledge to better understand genetic influences on drug resistance and potentially enable personalized epilepsy treatment.
Brief Report: OSA Evaluations for the Anaesthesiologist, Surgeon, Surgery Centresemualkaira
This short report presents a scope of the medical condition of Obstructive Sleep Apnea (OSA). Current methods for assessment and
diagnosis of OSA are presented. Complications and potential death
from untreated OSA places the anesthesiologist, surgeon and surgical center in a risk situation. Factors related to the risk factors
and points toward resolution are presented.
The document summarizes several clinical trends from internal corporate newsletters, including:
1) Psychotropic polypharmacy among office-based psychiatrists has increased from 1996-2006, with the average number of medications prescribed per visit doubling. This raises concerns about potential drug interactions and unclear benefits.
2) Osteoarthritis accounts for approximately 3 lost work days annually per patient costing employers $469-520 per patient in absenteeism costs, totaling $10 billion annually in the US.
3) A study found chronic kidney disease in 42% of individuals with undiagnosed diabetes and 18% of individuals with prediabetes, indicating the need for earlier CKD screening in pre
Similar to Anvs Annovis Presentation June 2020 (20)
Better Choice Company (OTCQB: BTTR) is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. Better Choice takes an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings, and positions its portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. The Company has a demonstrated, multi-decade track record of success selling trusted animal health and wellness products, and leverage its established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. Better Choice sells the majority of its dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats.
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020RedChip Companies, Inc.
Tiziana Life Sciences (NASDAQ: TLSA) is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
Tiziana Life Sciences (NASDAQ: TLSA) is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
Recruiter.com Group Inc. (OTCQB: RCRT) is disrupting the recruiting and staffing industry by aggregating the small and independent recruiters under a common platform, giving them access to large enterprise customers and advanced technologies.
Creating alcohol-free environments to increase productivity and save lives. That is the mission of Boulder, CO-based SOBRSafe, Inc. The company is integrating a preventative detection technology platform through partnership, licensing and acquisitions, and is in protype phase with its launch product: the patented, proprietary SOBRSafe® device - a non-invasive, touch-based identity verification and alcohol detection solution.
The document provides an investor overview of SPI Energy Co., Ltd., a solar energy company that operates solar project development, electricity production, residential solar solutions, and solar industry investments businesses around the world. It outlines SPI's business segments and assets, financial information, management team, and presents SPI as an undervalued investment opportunity in the growing solar industry given its large portfolio of solar assets.
Can-Fite is developing small molecule drugs that target the A3 adenosine receptor, including Piclidenoson for rheumatoid arthritis and psoriasis, and Namodenoson for liver cancer and NASH. Piclidenoson has shown efficacy in Phase II trials for rheumatoid arthritis and is currently in Phase III trials for rheumatoid arthritis and psoriasis. Namodenoson has shown efficacy in Phase II trials for liver cancer and is preparing for Phase III trials. Can-Fite is also exploring using Piclidenoson for COVID-19 given its anti-inflammatory and potential anti-viral properties.
SPI Energy (NASDAQ: SPI) is an established green energy player with global operations in key markets in Australia, Europe, Japan and the United States. It is leveraging its sizable solar platform and industry expertise to make strategic investment opportunities in green industries with significant growth and earnings potential and/or industries than can benefit from green power. Learn more at www.SpiGroupsInfo.com.
Creating alcohol-free environments to increase productivity and save lives. That is the mission of Boulder, CO-based SOBRSafe, Inc. The company is integrating a preventative detection technology platform through partnership, licensing and acquisitions, and is in protype phase with its launch product: the patented, proprietary SOBRSafe® device - a non-invasive, touch-based identity verification and alcohol detection solution.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
BioVie Inc. (OTCQB: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
Visit BIVIinfo.com to learn more.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Recruiter.com Group Inc. (OTCQB: RCRT) is disrupting the recruiting and staffing industry by aggregating the small and independent recruiters under a common platform, giving them access to large enterprise
customers and advanced technologies.
Creating alcohol-free environments to increase productivity and save lives. That is the mission of Boulder, CO-based SOBRSafe, Inc. The company is integrating a preventative detection technology platform through partnership, licensing and acquisitions, and is in protype phase with its launch product: the patented, proprietary SOBRSafe® device - a non-invasive, touch-based identity verification and alcohol detection solution.
COMSovereign Holding Corp. has assembled a portfolio of US-based communications technology companies whose combined capabilities enable connectivity across the entire data transmission spectrum. Through strategic acquisitions and organic research and development efforts, COMSovereign is seeking to become a U.S.-based pure-play communications provider able to provide LTE Advanced and 5G-NR telecom solutions to network operators and enterprises worldwide.
Better Choice Company (OTCQB: BTTR) is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. Better Choice takes an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings, and positions its portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. The Company has a demonstrated, multi-decade track record of success selling trusted animal health and wellness products, and leverage its established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. Better Choice sells the majority of its dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats.
Cuentas provides innovative mobile banking, mobility, and telecommunications solutions to underserved, unbanked, and emerging markets. The Company’s portfolio of fintech solutions meet the highest-volume services demand of the estimated 70 million underbanked and unbanked consumers in the US. ‘Underbanked’ refers to those who have limited or restricted access to banking services, due to poor credit or their international/resident status, and represent more than $1 trillion in total purchasing power.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
Under Pressure : Kenneth Kruk's StrategyKenneth Kruk
Kenneth Kruk's story of transforming challenges into opportunities by leading successful medical record transitions and bridging scientific knowledge gaps during COVID-19.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...nirahealhty
The South Beach Coffee Java Diet is a variation of the popular South Beach Diet, which was developed by cardiologist Dr. Arthur Agatston. The original South Beach Diet focuses on consuming lean proteins, healthy fats, and low-glycemic index carbohydrates. The South Beach Coffee Java Diet adds the element of coffee, specifically caffeine, to enhance weight loss and improve energy levels.
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
1. Attacks Alzheimer’s Disease and
Neurodegeneration by Improving the
Information Highway of the Nerve Cell
Axonal Transport
J u n e 2 0 2 0
Symbol: ANVS (NYSE American)
2. FORWARD-LOOKING STATEMENTS
Statements in this presentation contain “forward-looking statements” that are subject to
substantial risks and uncertainties. Forward-looking statements contained in this presentation
may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,”
“may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and
include, without limitation, statements regarding Annovis Bio, Inc.’s expectations regarding
the trading of its shares on the NYSE American market. Forward-looking statements are
based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to be accurate. These
and other risks and uncertainties are described more fully in the section titled “Risk Factors”
in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the
Securities and Exchange Commission. Forward-looking statements contained in this
presentation are made as of this date, and Annovis Bio, Inc. undertakes no duty to update
such information except as required under applicable law.
2
3. 3
▪ Annovis is developing drugs for Alzheimer's (AD) and Parkinson's disease (PD),
including the orphan indication Alzheimer's in Down Syndrome (AD-DS)
▪ Lead compound, ANVS401, is the only drug to improve axonal transport, the
information highway of the nerve cell, by attacking multiple neurotoxic proteins
▪ Two phase 2a studies
▪ AD trial already underway
▪ PD trial to be initiated
▪ Successful completion of the two phase 2a will allow start of two phase 3 studies
▪ Highly experienced and respected management team, great board and world
renowned scientific advisory board
HIGHLIGHTS
A novel approach to treat neurodegeneration is desperately needed
4. THE STATE OF ALZHEIMER’S DISEASE
▪ Alzheimer's is the most common cause of dementia, a
general term for memory loss and other cognitive
abilities serious enough to interfere with daily life.
Alzheimer's disease accounts for 60 to 80 percent of
dementia cases.
▪ 1 in 6 females and 1 in 11 males have the chance to
develop Alzheimer's during the remainder of their lives
at age 65.
▪ From 1998 to 2018 there have been over 500 failed
attempts at developing Alzheimer's drugs.
▪ The sector needs to rethink dementia, develop new
approaches and create new drugs.
4
5. ALZHEIMER’S DRUG TRIAL FAILURES
Have researchers been on the wrong track with amyloid?
5
The idea that sticky brain plaques cause Alzheimer’s disease began as an
interesting hypothesis and eventually became drug industry dogma. Now, after a
string of clinical trial failures, that hypothesis looks less credible than ever. But
how did nearly two decades of failure not convince the brightest minds in pharma
that it was time to move on?
Damian Garde & Alex Hogan
After amyloid failures, it’s
time to take a new tack
for treating Alzheimer’s
Raymond J. Tesi STAT News April 30, 2019
Aducanumab's failure puts
pressure on field to look
beyond amyloid
Ned PagliaruloMarch 22, 2019
Amyloid Plaque and Aβ is NOT The Only Answer
6. Chronic and acute brain insults lead to high levels of neurotoxic proteins,
to inflammation and neurodegeneration
Attacking one neurotoxic protein results in minimal effect
ANVS401 is the only drug to attack multiple neurotoxic proteins simultaneously
Amyloid β
AD / PD- Aβ Targeting Compounds
ANNOVIS’ DRUG TREATS AD AND PD
Tau
Tauopathies - AD - Tau Targeting Compounds
aSynuclein
PD / AD - aSYN Targeting Compounds
6
ACTIVATED MICROGLIA = High Inflammation
7. DISEASE
NEUROTOXIC PROTEIN
TARGET PRE-CLINICAL IND PHASE 1 PHASE 2
AD (AD-DS)
PD
TBI
Advanced
AD
APP, tau, aSYN
aSYN, APP
Tau, APP, aSYN
BChEl
PIPELINE
Oral drug for chronic
indications
injectabledrug for acute
traumatic events
oral drug for advancedAD
and dementia
7
8. 8
CORPORATE PATENT ESTATE
Patent/Application Subject Matter Status US Expiry US
Provisional
ANVS401 to treat viral and bacterial infections of
the brain, including Covid19
Pending 2041
PCT
ANVS401 and 405 - Method of use of MOA
for prevention and treatment of diseases
Pending 2038
PCT ANVS405 - Acute brain and nerve injuries Pending 2036
PCT
ANVS401 - pK/pD, low doses, formulations
Neurodegenerative Diseases
US 10,383,851; 07-2019
EP 2683242; 03-2020
2031
In-licensed
patents
Composition of matter, manufacturing,
method for treating AD and DS
Granted 2022-25
Composition
of Matter and
Method of Use
Process for
Production
Methods of Use:
pK/pD, Dose,
Formulations
Method of Use:
Acute Brain
and Nerve
Injuries
Method of Use:
Prevention
and Treatment
Multi-layer strategy
9. NEUROTRANSITTERS
THAT TRAVEL ACCROSS
THE AXON
Adrenaline
Noradrenaline
Dopamine
HOW NERVE CELLS WORK
In healthy nerve cells little packages containing neurotransmitters or nerve growth factors
travel unimpaired from the cell body through the axon to the synapse.
SOMA &
CELL BODY
DENDRITES
Serotonin
Gaba
Acetylcholine
Glutamine
Endorphins
SYNAPSE
9
Neurotoxic proteins limit the flow and speed at which
neurotransmitters travel along the axon resulting
in compromised nerve function
T H E I N F O R M A T I O N H I G H W A Y
10. NEUROTOXIC PROTEINS IMPAIR AXONAL
TRANSPORT AND CAUSE A TOXIC CASCADE
ANVS401 IMPROVES AXONAL TRANSPORT
AND IMPEDES THE TOXIC CASCADE
IMPAIRED AXONAL TRANSPORT
SLOWER SYNAPTIC TRANSMISSION
INFLAMMATION
DEATH OF NERVE CELLS
LOSS OF COGNITIVE AND
MOTOR FUNCTION
IMPROVED AXONAL TRANSPORT
INCREASED SYNAPTIC TRANSMISSION
NO INFLAMMATION
HEALTHY NERVE CELLS
IMPROVED COGNITIVE AND
MOTOR FUNCTION
HIGH LEVELS OF NEUROTOXIC
PROTEINS
ANVS401 LOWERS LEVELS OF
NEUROTOXIC PROTEINS
11. 11
RESULTS IN HUMANS
ANVS401 Lowers Neurotoxic Proteins in Spinal Fluid of MCI Patients
▪ In this proof of concept study, ANVS401 lowers the levels of APP/Aβ, tau/p-tau and
αSYN back to the levels seen in healthy volunteers
▪ It lowers the levels of the three neurotoxic proteins causing AD and PD
Maccecchini et al: JNNP 2012; 83: 894-902
12. NEURODEGENERATION IS AN AXONAL TRANSPORT
DISEASE
Axonal transport is responsible for: Normal Transport
The Normal Flow and Speed of vesicles carrying BDNF across the axon.
▪ Neurotransmitters GABA
(anxiety), ACh (cognition),
dopamine (movement),
serotonin (mood)
▪ Neurotrophic factors NGF,
BDNF
▪ All communication within
and between nerve cells
Newly published Nature Review
Article (September 2019):
“Axonal transport disruption is
linked to human neurological
conditions.”
Abnormal Transport
Shows the Blockage and Slowing of BDNF across the axon. Black areas demonstrate where
transport is slowed due to high levels of neurotoxic proteins.
TREATED WITH
The Flow and Speed of axonal transport is improved.
(120s)(88s)(88s)
APP, Ab42, C99 – Mobley, UCSD; aSYN – Isacson, Harvard; Lee, U.Penn;
Tau – U. Muenich & Zuerich; Htt – Mobley, UCSD; TDP43 – Taylor, Northwestern
Retrograde (0.5 frame/sec)
12
13. 13
ANVS401 LOWERS INFLAMMATORY MARKERS
Maccecchini et al: JNNP 2012; 83: 894-902
CSF Inflammatory Markers Significantly
Decrease After 10 Days of Oral ANVS401 in
MCI Patients
Inflammatory
Protein
CSF % of
Baseline
p-Value
Complement C3 -86.9% 0.0007
MCP-1 -87.5% 0.0007
YKL40 -72.7% 0.0113
sCD14 -26.1% 0.1159
Factor FH* 23.7% 0.4988
* Control Factor
14. 14
RESULTS IN ANIMALS
19 animal studies showed that ANVS401 and ANVS405 improved the affected function
✓ ANVS401 and ANVS405 increased memory and
learning in three animal models:
▪ AD tg mice
▪ DS trisomic mice
▪ TBI rats
✓ Improved gut motility in PD tg mice
✓ Stabilized brain chemistry in FTD tau tg mice
✓ Protected retinal cells in acute glaucoma in rats
15. 15
TWO PHASE 2 CLINICAL TRIALS IN AD AND PD
TRIALS
1) AD with 24 patients for one month
- ongoing (14 patients treated)
2) PD and AD with 68 patients for one month
- to start in June
ENDPOINTS
Target Engagement
Decrease in neurotoxic protein levels
Pathway Engagement
Increase in neurotransmitters and neurotrophic
factors
Lowering of inflammatory proteins
Lowering of neurodegeneration markers
Cognitive Outcomes and Functional Outcomes
16. 16
CLINICAL – OVERVIEW
CRO Parexel
Therapeutic Area Early Alzheimer's and Parkinson's Diseases
Phase 2
Design Double-Blind, Placebo-Controlled, 2-Cohort
Biomarker Study
Country United States
Sites Up to 15 Sites
Patients 68
Part 1 - Comparison of 14 AD vs 14 PD Patients
Part 2 - Dose Response in 40 PD Patients
17. 17
CLINICAL – SITE UPDATE
Backup
Approved for Selection
Contacted
In Progress
15 Sites
With Additional Back-Up Sites
18. CLINICAL - TIMELINES
The two-part clinical study is being set up at 15 sites in the US and will begin in
June 2020. The AD/PD comparison is projected to be concluded by the end of the
year and preliminary data will be available in early 1Q2021
The dose response is projected to be completed by mid summer next year
Start Up AD/PD Comparison
80 mg/day
Evaluation Evaluation
Dose Response
40, 20, 10, 5 mg/day
Close
December
2019
June
2020
January
2021
August
2021
18
19. 1% 2%
4%
8%
16%
47%
60-65 65-70 70-75 75-80 80-85 85+
19
MARKET PROJECTIONS
Source: Alzheimer‘s Association 2014; Incidence of AD in Relation to Age
Increase in Incidence with Aging of Population
Annual sales potential for US and worldwide
are over $100 billion dollars
20. CHIEF EXECUTIVES AND CHIEF ADVISORS
Jeffrey Cummings, MD, Chief Medical Advisor
Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts.
US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous
Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the
Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, director of the Deane F. Johnson Center for Neurotherapeutics at
UCLA and director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Cleveland and Florida. He is past president
of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited 30
books and published nearly 600 peer-reviewed papers.
20
Maria L. Maccecchini, PhD Founder, President & CEO
Founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
Was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony
Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; General Manager of Bachem Bioscience, the US
subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and
one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at
The Rockefeller University.
Jeffrey McGroarty, CPA, MBA, Chief Financial Officer
Jeff is a financial executive with experience in investor relations, working with analysts, creditors and financial institutions, planning
and analysis, capital allocation, SEC communications and reporting, accounting, acquisitions and turnarounds. He is experienced in
effectively managing complex projects, building professional relations and developing staff. Mr. McGroarty was previously employed
as CFO of Safeguard Scientifics, Interim Controller at Cephalon, Inc., Vice President-Financial Planning and Analysis of Exide
Technologies, Inc., and Senior Manager at PWC. Jeff’s MBA is from the Wharton School of Business.
William Mobley, MD, PhD Chief Scientific Advisor
Distinguished Professor, Department of Neurosciences Florence Riford Chair for Alzheimer Research and Associate Dean for
Neurosciences Initiatives. He is a member of the National Academy of Medicine. His research focuses on the neurobiology of
neurotrophic factor actions/signaling and on the hypothesis that malfunction of these mechanisms contribute to neuronal
dysfunction in developmental and age-related disorders of the neurosystem.
21. SCIENTIFIC ADVISORY BOARD
21
Sidney Strickland, PhD, Chairman
Vice President and Dean for Educational Affairs
and Research Professor, Patricia and John
Rosenwald Laboratory of Neurobiology and
Genetics at Rockefeller University. Dr. Strickland’s
laboratory investigates how dysfunction of the
circulatory system contributes to Alzheimer’s and
other neurodegenerative disorders. He will serve as
the Chairman of Annovis Bio’s SAB.
Peter Davies, PhD
Peter Davies received his B.Sc. and Ph.D. both in
Biochemistry from the University of Leeds. He was
a post-doctoral fellow at the University of
Edinburgh, Scotland before joining the staff of the
Medical Research Council Brain Metabolism Unit
in Edinburgh in 1974, where he began his research
on Alzheimer’s disease. He is presently the Director
of the Litwin-Zucker Research Center.
Jeffrey Cummings, MD
Dr. Cummings completed Neurology residency and a
Fellowship in Behavioral Neurology at Boston University,
Massachusetts. US training was followed by a Research
Fellowship in Neuropathology and Neuropsychiatry at the
National Hospital for Nervous Diseases, London, England.
Dr. Cummings was formerly Professor of Neurology and
Psychiatry, Director of Alzheimer’s Disease Research and
Director of the Center for Neurotherapeutics at UCLA. He
was Director of the Cleveland Clinic Lou Ruvo Center for
Brain Health in Las Vegas, Cleveland and Florida.
William Mobley, MD, PhD
Dr. Mobley is Distinguished Professor, Department
of Neurosciences Florence Riford Chair for
Alzheimer Research and Associate Dean for
Neurosciences Initiatives. He is a member of the
National Academy of Medicine. His research
focuses on the neurobiology of neurotrophic
factor actions/signaling and on the hypothesis
that malfunction of these mechanisms contribute
to neuronal dysfunction in developmental and
age-related disorders of the neurosystem.
Gregory Petsko, PhD
He is a member of the National Academy of Sciences,
the National Academy of Medicine, the American
Academy of Arts and Sciences and the American
Philosophical Society. His research interests are directed
towards understanding the biochemical bases of
neurological diseases like Alzheimer’s, Parkinson’s, and
ALS discovering treatments (especially by using structure-
based drug design), that could therapeutically affect
those biochemical targets, and seeing any resulting drug
candidates tested in humans. He has also made key
contributions to the field of protein crystallography.
Rudolph E. Tanzi, PhD
Dr. Tanzi has published over 500 research papers and has
received the highest awards in his field, including the
Metropolitan Life Foundation Award, Potamkin Prize,
Ronald Reagan Award, Silver Innovator Award, and
many others. He was named to TIME magazine’s list of
TIME100 Most Influential People in the World (2015), and
received the Smithsonian American Ingenuity Award, the
top national award for invention and innovation. He co-
authored the popular trade books “Decoding Darkness”,
New York Times bestseller, “Super Brain”, and international
bestseller “Super Genes”.
22. 22
Michael B. Hoffman
Chairman
Mr. Hoffman is the Founder and Managing Partner
of Stone Capital Partners, a private equity firm
focused on power and renewable energy. He was
Partner of Riverstone, senior managing director at
the Blackstone Group and managing director at
Smith Barney, Harris Upham & Co. He serves as
Chairman of Onconova, Annovis Bio, Curative and
is on the Board of Rockefeller University.
Claudine E. Bruck, PhD
Pharmaceutical executive and scientist with strong
entrepreneurial drive. Exhibited successes in
building a therapeutic research unit de novo and
leading discovery and clinical development of
biological (vaccines, biopharmaceuticals) and
small molecule medicines as well as an ophthalmic
drug portfolio. With creativity and a strong results-
focus, she is energized to challenge and lead
teams. Extensive Pharmaceutical industry
experience spans drug discovery and
development across several therapeutic.
Mark White
Mark is a biopharmaceutical executive with
global marketing, business development and
sales experience. Currently, Mark is an
independent consultant and a member of Robin
Hood Ventures, a Philadelphia based angel
investor group. Previously, Mark held senior level
roles at Pfizer in marketing and commercial
development, where he led the successful global
launches of Inspira, Revatio, Lyrica and Xeljanz. In
his last position, he was Vice President
Worldwide Marketing, with global responsibility
for new product development and in-line
marketing for Pfizer’s Inflammation
Therapeutic Area.
Robert M. Whelan, Jr.
Mr. Whelan brings over 35 years of corporate
finance and investment banking experience to
Annovis’ Board of Directors. Since 2001, Mr.
Whelan has been President of Whelan &
Company, LLC, providing financial consulting,
valuation and strategic services to public and
private companies in the technology,
healthcare and alternative energy industries.
From 1999 to 2001, Mr. Whelan served as Vice
Chairman, Prudential Volpe Technology Group.
Prior to then, Mr. Whelan was a senior executive
with Volpe Brown Whelan, a private technology
and healthcare investment banking, brokerage
and asset management firm.
.
Maria L. Maccecchini, PhD
Executive Board Member
Founded Annovis in May 2008 to develop better
therapeutics for Alzheimer’s, Parkinson’s and other
neurodegenerative diseases. Founder and CEO of
Symphony Pharmaceuticals/Annovis focused on
protecting brain cells after stroke. It sold in 2001 to
Transgenomic.
BOARD OF DIRECTORS
23. INVESTMENT SUMMARY
A novel approach to treat neurodegeneration is desperately needed
▪ The markets for AD and PD drugs are in the multibillions of dollars
and growing
▪ Annovis has a novel solution to stop the course of AD and PD
▪ ANVS401 improves axonal transport and homeostasis in the
brain and recovers the affected function
▪ The successful completion of our two Phase 2a studies will
provide optimal information on target and pathway
engagement in AD and PD and allows us to move to two Phase
3 studies
23
24. Improves THE FLOW of Axonal Transport
in Alzheimer’s Disease and
Neurodegeneration
CONTACT US
1055 Westlakes Drive
Suite 300
Berwyn, PA 19312
+1 (610) 727 3913
info@annovisbio.com
www.annovisbio.comSymbol: ANVS (NYSE American)